U.S. Markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3700-0.1900 (-5.34%)
At close: 4:00PM EDT

Longeveron Inc.

1951 NW 7th Avenue
Suite 520
Miami, FL 33136
United States
305 909 0840

Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Joshua Michael HareCo-Founder, Chief Science Officer & Chairman270kN/A1963
Mr. Geoff Green M.B.A.Chief Exec. Officer234.33kN/A1974
Mr. James ClavijoCFO & Treasurer171.81kN/A1966
Mr. Paul T. Lehr J.D.International Exec. Director, Gen. Counsel & Sec.182.65kN/A1968
Dr. Anthony Oliva Ph.D.Sr. VP of Scientific AffairsN/AN/A1971
Dr. Dan Gincel Ph.D.Sr. VP of Strategic Collaborations & Scientific AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Corporate Governance

Longeveron Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.